🔗 Share this article

The initial novel therapies for gonorrhoea in many years are being described as a "huge turning point" in the fight against superbug strains of the infection, according to researchers.

A Global Health Concern

Cases of gonorrhoea are increasing globally, with estimates suggesting in excess of 82 million instances per year. Notably increased rates are reported in the African continent and countries within the World Health Organization's Western Pacific region, which encompasses China and Mongolia to New Zealand. In England, cases have hit a record high, while figures across Europe in 2023 were significantly elevated compared to the rates from 2014.

“The approval of fresh medications for gonorrhoea is an significant and necessary development in the face of growing infection rates, escalating drug resistance and the extremely scarce available drugs presently on offer.”

Medical experts are particularly alarmed about the increase in treatment-resistant strains. The global health body has listed it as a "critical concern". Recent surveillance showed that resistance to key first-line drugs like cefixime and ceftriaxone jumped significantly between 2022 and 2024.

Two New Drugs Receive Clearance

Zoliflodacin, marketed under the name Nuzolvence, was authorized by the US Food and Drug Administration in mid-December for combating gonorrhoea. This disease can lead to serious health problems, including the inability to conceive. Researchers hope that focused deployment of this new drug will help hinder the emergence of superbugs.

Gepotidacin, developed by the drugmaker GSK, gained clearance in close succession. This treatment, which is employed against urinary tract infections, was proven in research to be successful in treating antibiotic-resistant forms of the gonorrhoea bacteria.

A Novel Partnership

This new treatment was the result of a unique collaborative effort for antibiotic development. The charitable organization GARDP partnered with the pharmaceutical company its industry partner to develop it.

“This approval signifies a major breakthrough in the therapy of multidrug-resistant gonorrhoea, which up to this point has been staying ahead of medical innovation.”

Testing Data and Global Access

As per results detailed in a prominent scientific publication, the new drug successfully treated over nine in ten of cases of the STI. This establishes an similar efficacy with the typical regimen, which involves an injection and a pill. The trial included hundreds of patients from several countries including the United States, Thailand, South Africa, and European nations.

Through the arrangement of its unique model, the non-profit has the rights to register and commercialise the drug in numerous low-income and middle-income countries.

Doctors directly involved have voiced hope. Access to a single-dose, oral treatment such as this is described as a "critical tool" for gonorrhoea control. This is deemed crucial to reduce the burden of the illness for people and to halt the transmission of highly drug-resistant gonorrhoea globally.